{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:22:28Z","timestamp":1783948948777,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Biomedical Advanced Research and Development AuthorityBiomedical Advanced Research and Development Authority (BARDA)","award":["HHSO100201400003I"],"award-info":[{"award-number":["HHSO100201400003I"]}]},{"name":"Biomedical Advanced Research and Development AuthorityBiomedical Advanced Research and Development Authority (BARDA)","award":["HHSO10033002T"],"award-info":[{"award-number":["HHSO10033002T"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.vaccine.2018.11.069","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T18:30:50Z","timestamp":1544639450000},"page":"435-443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS)"],"prefix":"10.1016","volume":"37","author":[{"given":"Christine M.","family":"Oshansky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo Ellen","family":"Schweinle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Biscardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"DeBeauchamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrina","family":"Pavetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Wollish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Webby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Cioce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben O.","family":"Donis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick A.","family":"Bright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.11.069_b0005","unstructured":"Centers for Disease Control and Prevention. Influenza Risk Assessment Tool (IRAT). Internet."},{"key":"10.1016\/j.vaccine.2018.11.069_b0010","unstructured":"U.S. department of health and human services pandemic influenza plan 2017 Update. In: Services HaH, editor. Centers for Disease Control and Prevention; 2017."},{"key":"10.1016\/j.vaccine.2018.11.069_b0015","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2018.11.069_b0020","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1086\/527489","article-title":"Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults","volume":"197","author":"Bernstein","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.11.069_b0025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.2015.7916","article-title":"Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial","volume":"314","author":"Jackson","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2018.11.069_b0030","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jama.2014.12609","article-title":"Immunogenicity of avian influenza A\/Anhui\/01\/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial","volume":"312","author":"Belshe","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2018.11.069_b0035","doi-asserted-by":"crossref","first-page":"ofu102","DOI":"10.1093\/ofid\/ofu102","article-title":"Point-of-use mixing of influenza H5N1 vaccine and MF59 adjuvant for pandemic vaccination preparedness: antibody responses and safety. A Phase 1 Clinical Trial","volume":"1","author":"Mulligan","year":"2014","journal-title":"Open For Infect Dis"},{"key":"10.1016\/j.vaccine.2018.11.069_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/5f2ae0fb-53f1-48c2-aa19-9114765ba029","article-title":"MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults","volume":"4","author":"Banzhoff","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.11.069_b0045","doi-asserted-by":"crossref","first-page":"ofu091","DOI":"10.1093\/ofid\/ofu091","article-title":"Safety, reactogenicity, and immunogenicity of inactivated monovalent influenza A(H5N1) virus vaccine administered with or without AS03 adjuvant","volume":"1","author":"Chen","year":"2014","journal-title":"Open For Infect Dis"},{"key":"10.1016\/j.vaccine.2018.11.069_b0050","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/infdis\/jis427","article-title":"Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons","volume":"206","author":"Jackson","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.11.069_b0055","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4142\/jvs.2017.18.S1.269","article-title":"global spread, and pathogenicity of highly pathogenic avian influenza H5Nx clade 2.3.4.4","volume":"18","author":"Lee","year":"2017","journal-title":"J Vet Sci"},{"key":"10.1016\/j.vaccine.2018.11.069_b0060","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.coviro.2016.02.005","article-title":"Emergence and dissemination of clade 2.3.4.4 H5Nx influenza viruses-how is the Asian HPAI H5 lineage maintained","volume":"16","author":"Claes","year":"2016","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2018.11.069_b0065","unstructured":"Sanofi Pasteur VRBPAC Briefing Document: H5N1 Influenza Virus Vaccine, A\/Vietnam\/1203\/2004 (Clade 1) 90 mcg\/ml. 2007."},{"key":"10.1016\/j.vaccine.2018.11.069_b0070","unstructured":"Memorandum: February 27, 2007b Meeting Topic 1: Safety and Immunogenicity of H5N1 Influenza Virus Vaccine, A\/Vietnam\/1203\/2004 (clade 1), 90\u03bcg\/mL, Manufactured by Sanofi Pasteur. In: Health and Human Services FaDA, Center for Biologics Evaluation and Research (CBER), Office of Vaccine Research and Review, Division of Vaccines and Review and the Division of Vaccines and Related Product Applications, editor."},{"key":"10.1016\/j.vaccine.2018.11.069_b0075","unstructured":"(WHO) WHO. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO; 2018."},{"key":"10.1016\/j.vaccine.2018.11.069_b0080","unstructured":"Research FaDACfBEa. Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines. In: Services USDoHaH, editor; 2007."},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.11.069_b0085","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2014.11.062","article-title":"Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults","volume":"33","author":"Black","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.069_b0090","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1056\/NEJMc0805274","article-title":"Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1","volume":"359","author":"Stephenson","year":"2008","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2018.11.069_b0095","series-title":"Inactivated and adjuvanted influenza vaccines","author":"Del Giudice","year":"2014"},{"key":"10.1016\/j.vaccine.2018.11.069_b0100","unstructured":"Package Insert: Sanofi Pasteur Influenza Virus Vaccine, H5N1; 2007."},{"key":"10.1016\/j.vaccine.2018.11.069_b0105","unstructured":"Package Insert: Seqirus Inc. FLUAD; 2017."},{"key":"10.1016\/j.vaccine.2018.11.069_b0110","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1016\/j.vaccine.2009.08.101","article-title":"MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database","volume":"27","author":"Pellegrini","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.069_b0115","doi-asserted-by":"crossref","first-page":"S555","DOI":"10.1093\/infdis\/jix001","article-title":"Cross-reactive antibody responses to novel H5Nx influenza viruses following homologous and heterologous prime-boost vaccination with a prepandemic stockpiled A(H5N1) vaccine in humans","volume":"216","author":"Levine","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.11.069_b0120","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2014.11.018","article-title":"Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial","volume":"33","author":"Langley","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.069_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095496","article-title":"Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization","volume":"9","author":"Khurana","year":"2014","journal-title":"PLoS One"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18316323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18316323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T12:22:32Z","timestamp":1605615752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18316323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0264410X18316323"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.069","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}